CURE staff

KEYNOTE-522 trial data shows adding Keytruda to chemotherapy drastically improves long-term survival for high-risk, early-stage TNBC.

ASCO 2026: MajesTEC-9 trial shows Tecvayli cuts death risk by 40% and improves outcomes in relapsed/refractory multiple myeloma patients.

Lifyorli plus Abraxane improved survival in platinum-resistant ovarian cancer regardless of prior taxane use, according to updated ROSELLA data.

Study finds breast cancer patients with vitamin D deficiency are three times more likely to report moderate pain and receive more opioids after surgery

Talking about what matters most with your nurses can improve your care and comfort during intensive treatments like stem cell transplants.

New research shows maintaining physical function and nutrition may help patients with advanced liver cancer stay on treatment longer and live longer.

Two-time acute myeloid leukemia survivor Amanda Ferraro teamed up with CURE to share the 10 things that helped her get through cancer treatment — offering hope, strength and support for others navigating their own journey.

The FDA approved Tecentriq for patients with muscle-invasive bladder cancer who still have detectable signs of tumor DNA in their blood after surgery.

FDA approves oral Inqovi plus Venclexta for newly diagnosed AML in older adults or those with comorbidities, expanding non-intensive options.

FDA grants accelerated approval to Beqalzi (sonrotoclax) for relapsed or refractory mantle cell lymphoma in adults after prior therapies

Learn about the FDA approval of Veppanu, the first PROTAC for ER+/HER2- metastatic breast cancer with ESR1 mutations.

A SEER-Medicare study found nearly half of older patients with metastatic non–small cell lung cancer never received systemic therapy.

Diakonos Oncology receives FDA Fast Track status for DOC1021, a dendritic cell immunotherapy for patients with advanced or metastatic skin cancer.

Phase 3 VIKTORIA-1 trial shows gedatolisib triplet therapy significantly extends progression-free survival for HR+/HER2- advanced breast cancer.

The FDA approved a once-daily extended-release tablet, Jakafi XR, for patients with myelofibrosis, polycythemia vera and GVHD.

Following FDA approval, Veppanu (vepdegestrant) provides a new oral treatment option for patients with ESR1-mutated, ER+/HER2- metastatic breast cancer.

Phase 3 trial shows Datroway significantly extended overall and progression-free survival in patients with previously untreated, advanced TNBC ineligible for immunotherapy.

The phase 3 LITESPARK-012 trial did not improve survival in advanced kidney cancer, highlighting ongoing need for better first-line treatments.

FDA grants Priority Review for Padcev plus Keytruda in muscle-invasive bladder cancer, showing improved survival and reduced recurrence risk.

The NexTGen team launches the world's largest CAR-T cell trial for pediatric solid tumors, offering new hope for children with relapsed cancer.

Darlifarnib plus Cabometyx showed tumor responses in resistant kidney cancer following prior treatment.

Patients with cancer have a new generic option for methotrexate injection following FDA approval of a therapeutic equivalent for multiple conditions.

The FDA accepted an investigational new drug application for chemo-related neuropathy, advancing a potential non-opioid treatment into a clinical trial.

The OPTIMAL trial finds oral DHP107 is as effective as IV paclitaxel for patients with advanced breast cancer while reducing side effects like neuropathy.

Elraglusib plus chemotherapy doubled one-year survival in metastatic pancreatic cancer, showing improved outcomes in a phase 2 trial.

A 30-year study reveals one in six AYA cancer survivors develop a new primary neoplasm, with risks highest for breast and oral cancer survivors.

PDS01ADC showed high response rates in metastatic colorectal cancer in a phase 2 trial after prior treatment.

Emactuzumab improved tumor response and function in TGCT, showing rapid, durable benefits in a phase 3 trial with a short-course treatment approach.

Daraxonrasib improved overall survival versus chemotherapy in metastatic pancreatic cancer.

Gotistobart reduced risk of death by 54% and doubled 12-month survival vs chemotherapy in advanced squamous NSCLC after prior treatment.